ArticleJournal of neuroimmunology2012
Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.
Article in Journal of neuroimmunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- The effect of cannabinoid type 2 receptor agonist on morphine tolerance.IBRO neuroscience reports · 2024Review
- Transcriptional and epigenetic regulation of microglia in substance use disorders.Molecular and cellular neurosciences · 2023Review
- Modulation of Morphine Analgesia, Antinociceptive Tolerance, and Mu-Opioid Receptor Binding by the Cannabinoid CB2 Receptor Agonist O-1966.Frontiers in pharmacology · 2022Article
- Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders.Frontiers in psychiatry · 2022Review
- Sex differences in the expression of the endocannabinoid system within V1M cortex and PAG of Sprague Dawley rats.Biology of sex differences · 2021Article
- Repeated morphine exposure activates synaptogenesis and other neuroplasticity-related gene networks in the dorsomedial prefrontal cortex of male and female rats.Drug and alcohol dependence · 2021Article
- The Effects of Repeated Morphine Treatment on the Endogenous Cannabinoid System in the Ventral Tegmental Area.Frontiers in pharmacology · 2021Article
- Thiazolidine Derivatives Attenuate Carrageenan-Induced Inflammatory Pain in Mice.Drug design, development and therapy · 2021Article
- The cannabinoid CBEuropean journal of pharmacology · 2020Article
- Electroacupuncture alleviates morphine‑induced hyperalgesia by regulating spinal CB1 receptors and ERK1/2 activity.Molecular medicine reports · 2019Article
- Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management.Frontiers in immunology · 2019Review
- The Benzimidazole Derivatives, B1 (Frontiers in neuroscience · 2019Article
- Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.Frontiers in cellular neuroscience · 2019Article
- Slowly Signaling G Protein-Biased CBMolecular pharmacology · 2018Article
- Tanshinone IIA Attenuates Diabetic Peripheral Neuropathic Pain in Experimental Rats via Inhibiting Inflammation.Evidence-based complementary and alternative medicine : eCAM · 2018Article
- Biphalin, a Dimeric Enkephalin, Alleviates LPS-Induced Activation in Rat Primary Microglial Cultures in Opioid Receptor-Dependent and Receptor-Independent Manners.Neural plasticity · 2017Article
- Review
- Time-Dependent Protection of CB2 Receptor Agonist in Stroke.PloS one · 2015Article
- Curcumin attenuates diabetic neuropathic pain by downregulating TNF-α in a rat model.International journal of medical sciences · 2013Article
- Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization. Since activation of glial CB2 cannabinoid receptors attenuates spinal glial activation in neuropathies, we hypothesized that CB2 agonists may also attenuate sustained morphine-mediated spinal glial activation and pain sensitization. Our data indicate that co-administration of a CB2-selective agonist (AM 1241) attenuates morphine (intraperitoneal; twice daily; 6 days)-mediated thermal hyperalgesia and tactile allodynia in rats. A CB2 (AM 630) but not a CB1 (AM 251) antagonist mitigated this effect. AM 1241 co-treatment also attenuated spinal astrocyte and microglial marker and pro-inflammatory mediator (IL-1β, TNFα) immunoreactivities in morphine-treated rats, suggesting that CB2 agonists may be useful to prevent the neuroinflammatory consequences of sustained morphine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.